Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor

A method of treating a glioma in a subject in need thereof, comprising:

• administering to the subject a therapeutically effective amount of a compound of formula (Ic):
• or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor selected from nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab, wherein:
• X3 and X4 are each independently selected from the group consisting of hydrogen, halogen, unsubstituted C1-8 alkyl, and C1-8 haloalkyl;
• Y9 is selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C1-8 alkyl;
• and
• Y11 is CH—, —N—, or −N+(O)−—.